Suppr超能文献

泰国的青蒿素耐药遏制项目。二:柬埔寨边境省份间恶性疟疾病例对青蒿琥酯-甲氟喹联合疗法的反应。

Artemisinin resistance containment project in Thailand. II: Responses to mefloquine-artesunate combination therapy among falciparum malaria patients in provinces bordering Cambodia.

机构信息

Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

出版信息

Malar J. 2012 Aug 28;11:300. doi: 10.1186/1475-2875-11-300.

Abstract

BACKGROUND

The area along the Thai-Cambodian border is considered an epicenter of anti-malarial drug resistance. Recently, parasite resistance to artemisinin-based therapies has been reported in the area. The artemisinin resistance containment project was initiated in November 2008, with the aim to limit resistant parasites and eliminate malaria in this region. This study describes the response to artemisinin-based therapy among falciparum malaria patients in the area, using data from the malaria surveillance programmed under the containment project.

METHODS

The study was conducted in seven provinces of Thailand along the Thai-Cambodian border. Data of Plasmodium falciparum-positive patients during January 2009 to December 2011 were obtained from the electronic malaria information system (eMIS) Web-based reporting system. All P. falciparum cases were followed for 42 days, as the routine case follow-up protocol. The demographic characteristics of the patients were described. Statistical analysis was performed to determine the cure rate of the current standard anti-malarial drug regimen--mefloquine-artesunate combination therapy (MAS). The proportion of patients who remained parasite-positive at each follow-up day was calculated. In addition, factors related to the delayed parasite clearance on day-3 post-treatment, were explored.

RESULTS

A total of 1,709 P. falciparum-positive cases were reported during the study period. Almost 70% of falciparum cases received MAS therapy (n = 1,174). The majority of cases were males, aged between 31 and 50 years. The overall MAS cure rate was > 90% over the three-year period. Almost all patients were able to clear the parasite within 7 to 14 days post-treatment. Approximately 14% of patients undergoing MAS remained parasite-positive on day-3. Delayed parasite clearance was not significantly associated with patient gender, age, or citizenship. However, delayed parasite clearance varied across the study area.

CONCLUSION

Anti-malarial drug-resistant parasites should be closely monitored in the area along the Thai-Cambodian border. Although the MAS cure rate in this study area was above 90%, an increasing trend of treatment failure has been reported in neighboring parts. Effective malaria surveillance is an important component to monitor drug-resistance in the malaria containment project.

摘要

背景

泰柬边境地区被认为是抗疟药物耐药性的中心地带。最近,该地区已报告寄生虫对青蒿素类药物治疗产生耐药性。抗疟药物耐药性遏制项目于 2008 年 11 月启动,旨在限制耐药寄生虫并消除该地区的疟疾。本研究使用遏制项目下的疟疾监测计划中的数据,描述了该地区间日疟原虫阳性患者对青蒿素类药物治疗的反应。

方法

该研究在泰国与柬埔寨接壤的七个省份进行。从电子疟疾信息系统(eMIS)网络报告系统中获取了 2009 年 1 月至 2011 年 12 月间日疟原虫阳性患者的数据。所有间日疟原虫病例均按照常规病例随访方案进行 42 天随访。描述了患者的人口统计学特征。统计分析用于确定当前标准抗疟药物治疗方案-甲氟喹-青蒿琥酯联合疗法(MAS)的治愈率。计算了每个随访日仍有寄生虫阳性的患者比例。此外,还探讨了与治疗后第 3 天寄生虫清除延迟相关的因素。

结果

研究期间共报告了 1709 例间日疟原虫阳性病例。近 70%的间日疟原虫病例接受了 MAS 治疗(n=1174)。大多数病例为男性,年龄在 31 至 50 岁之间。三年期间,MAS 的总体治愈率超过 90%。几乎所有患者都能在治疗后 7 至 14 天内清除寄生虫。大约 14%接受 MAS 治疗的患者在第 3 天仍有寄生虫阳性。寄生虫清除延迟与患者性别、年龄或国籍无显著相关性。然而,寄生虫清除延迟在研究区域之间存在差异。

结论

应密切监测泰柬边境地区的抗疟药物耐药寄生虫。尽管本研究地区的 MAS 治愈率高于 90%,但在邻国已报告治疗失败的趋势有所增加。有效的疟疾监测是监测遏制疟疾项目中药物耐药性的重要组成部分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca40/3445821/e1a4f83c1889/1475-2875-11-300-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验